Embecta Corp. (EMBC) Faces Securities Class Action Over Insulin Pen Needle Disclosure – Investors with Losses Encouraged to Contact Hagens Berman

Hagens Berman is investigating Embecta regarding alleged federal securities law violations tied to disclosures about its insulin pen needle business. The complaint alleges the company misled investors about business stability before reporting a significant revenue decline and slashing FY26 EPS guidance by roughly 43% on May 5, 2026. Investors who purchased shares between Nov. 25, 2025, and May 4, 2026, are encouraged to contact the firm before the Aug.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.